About: Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Creator	Chan, Reddy, Brownstone, Nicholas Bridget, A Liao, Myers, Quinn, G Stephanie, Y Thibodeaux, Tina, Bhutani Vidhatha, D
Source	Medline; PMC
abstract	The outbreak of the novel coronavirus known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causing COVID-19 was first reported in late December 2019. Many patients with psoriasis on biologic therapy have asked their medical providers about the effect of biologics on COVID-19. However, it is currently unknown how biologic therapy for psoriasis might impact patients with psoriasis and COVID-19. In this article, we report on the clinical course of two patients on biologic medication for psoriasis who developed COVID-19 and successfully recovered from SARS-CoV-2 infection. Both patients presented with fever and respiratory symptoms, but neither patient required hospitalization. While more research is needed, it is reassuring to know that successful recovery is possible after COVID-19 infection in patients on biologic therapy for psoriasis.
has issue date	2020-05-29(xsd:dateTime)
bibo:doi	10.1007/s13555-020-00394-8
bibo:pmid	32468230
has license	cc-by-nc
sha1sum (hex)	e54be814c721ec270866d4fbc1129369accfdd0e
schema:url	https://doi.org/10.1007/s13555-020-00394-8
resource representing a document's title	Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
has PubMed Central identifier	PMC7255969
has PubMed identifier	32468230
schema:publication	Dermatol Ther (Heidelb)
resource representing a document's body	covid:e54be814c721ec270866d4fbc1129369accfdd0e#body_text
is schema:about of	named entity 'Coronavirus' named entity 'Infection' named entity 'COVID' named entity 'Coronavirus Disease' named entity 'informed consent' named entity 'interleukin-17' named entity 'IL-12' named entity 'electrocardiogram' named entity 'biologic therapy' named entity 'symptom' named entity 'COVID' named entity 'coronavirus' named entity 'COVID-19 pandemic' named entity 'rheumatoid arthritis' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'BSA' named entity 'tumor necrosis factor alpha' named entity 'pathogenicity' named entity 'psoriasis' named entity 'psoriasis' named entity 'inflammatory response' named entity 'shortness of breath' named entity 'COVID' named entity 'adalimumab' named entity 'symptom' named entity 'Creative Commons licence' named entity 'IL-23' named entity 'Data sharing' named entity 'patient-years' named entity 'adalimumab' named entity 'long-term' named entity 'COVID' named entity 'biologic therapies' named entity 'US Food and Drug Administration' named entity 'comorbidities' named entity 'National Institutes of Health' named entity 'TNFa' named entity 'plaque psoriasis' named entity 'fatigue' named entity 'biologic therapy' named entity 'ustekinumab' named entity 'acetaminophen' named entity 'symptom' named entity 'BSA' named entity 'loss of smell' named entity 'complete blood count' named entity 'clinical trials' named entity 'clinical trials' named entity 'biologic therapy' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'supportive therapy' named entity 'biologic therapy' named entity 'incidence rates' named entity 'sore throat' named entity 'infection' named entity '300 million' named entity '20%' named entity 'immunomodulatory' named entity 'hypertension' named entity 'infliximab' named entity 'infection' named entity 'tissue damage' named entity 'Amgen' named entity 'medical data' named entity 'nausea' named entity 'adalimumab' named entity 'fever' named entity 'zinc supplements' named entity 'Stephanie Chan' named entity 'gastrointestinal upset'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software